A Phase I Clinical Study of BBI503 in Adult Patients With Advanced Solid Tumors

Trial Profile

A Phase I Clinical Study of BBI503 in Adult Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Amcasertib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Boston Biomedical
  • Most Recent Events

    • 11 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 06 Jun 2017 Safety and efficacy results in patients with adenoid cystic carcinoma (n=14), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 Safety and efficacy results in patients with advanced head and neck cancer (n=21), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top